


# Claims

1. A benzylamine derivative represented by formula (1):

[F1]



[wherein  $X^1$  represents  $-N(CH_3)-$ ,  $-NH-$ , or  $-O-$ ;

$X^2$  represents a single bond,  $-NH-$ , an amido bond, an ester bond,  $-O-$ ,  $-S-$ , or  $-CO-$ ;

each of  $X^3$  and  $X^4$  represents a hydrogen atom or a halogen atom;

$R^1$  represents a hydrogen atom; a lower alkyl group; a phenyl group which may be substituted by 1 to 3 halogen atoms or cyano groups; a benzyl group which may be substituted by 1 to 3 lower alkyl groups, cyano groups, halogeno(lower alkyl) groups, or lower alkoxy groups; a benzoyl group which may be substituted by 1 to 3 lower alkyl groups, hydroxyl groups, halogeno(lower alkyl) groups, or lower alkoxy groups; a lower alkanoyl group which may be substituted by 1 to 5 halogen atoms, amino groups, or carbamoyl groups; a hydroxyl group; a carbamoyl group; a lower alkylsulfonyl group; a lower alkoxy-carbonyl-lower alkyl group; a thienylcarbonyl group; a pyridylcarbonyl group; a lower alkylcarbonyl group; or a

phenoxycarbonyl group);

$R^2$  represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkylsulfonyl group, a C3-C7 cycloalkyl group, a C6-C14 cycloalkyl-alkyl group, a C6-C14 aryl group, a C6-C14 aryloxy group, a C6-C14 aryloxy-lower alkyl group, C6-C14 arylthio-lower alkyl group, a C7-C16 aralkyl group, a lower alkoxycarbonyl-lower alkyl group, a lower alkoxy-lower alkyl group, an amino-lower alkyl group, a C7-C16 aralkyl group substituted by a C3-C7 cycloalkyl group, a halogeno(lower alkyl)carbonyl group, an indanyl group, a 1,2,3,4-tetrahydronaphthalenyl group, a xanthenyl group, a piperidinyl group, a pyrrolidinyl group, a morpholino group, a tetrahydroisoquinolyl group, an indolyl group, a chromenyl group, an isobenzofuranyl group, a tetrahydropyranyl group, a benzothienyl group, an adamantyl group, an adamantyl(lower alkyl) group, a fluorenyl group, a fluorenyl(lower alkyl) group, a pyridyl(lower alkyl) group, or an amino group which may be substituted by a phenyl group or a lower alkyl group (wherein a ring hydrogen of these group may be substituted by 1 to 5 atoms or groups selected from among a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group, an oxo group, a halogeno(lower alkyl) group, a C6-C14 aryl group, and a lower alkylamino group;

when  $R^3$  represents a (lower alkanoyl)amino group, an amino(lower alkanoyl) group, an amino(lower alkanoyl)amino group, a di(lower alkyl)carbamoylamino group, or a C7-C16 aralkyloxy(lower alkyl) group,  $R^4$  represents a hydrogen atom;

or R<sup>3</sup> and R<sup>4</sup> may together form -SOCH<sub>2</sub>-, -SO<sub>2</sub>CH<sub>2</sub>-, -NHCOCH<sub>2</sub>-, -CH(OH)CH<sub>2</sub>-, -OCH<sub>2</sub>-, or -C(=NOH)CH<sub>2</sub>-; R<sup>5</sup> represents a hydrogen atom or a lower alkyl group; n<sub>1</sub> is 1 or 2; and n<sub>2</sub> is 0 or 1] or a salt thereof.

2. A benzylamine derivative as described in claim 1 or a salt thereof, wherein R<sup>3</sup> and R<sup>4</sup> together form -SOCH<sub>2</sub>-, -SO<sub>2</sub>CH<sub>2</sub>-, -NHCOCH<sub>2</sub>-, -CH(OH)CH<sub>2</sub>-, -OCH<sub>2</sub>-, or -C(=NOH)CH<sub>2</sub>-.

3. A benzylamine derivative as described in claim 1 or 2 or a salt thereof, wherein X<sup>1</sup> is -N(CH<sub>3</sub>)- or -O-.

4. A benzylamine derivative as described in any one of claims 1 to 3 or a salt thereof, wherein X<sup>2</sup> is a single bond, -NH-, an amido bond, an ester bond, -O-, or -CO-.

5. A benzylamine derivative as described in any one of claims 1 to 4 or a salt thereof, wherein R<sup>2</sup> is a C7-C16 aralkyl group, a lower alkyl group, a C6-C14 aryl group, a C3-C7 cycloalkyl group, or an amino group which may be substituted by a phenyl group or a lower alkyl group

6. A drug containing, as an active ingredient, a benzylamine derivative as recited in any one of claims 1 to 5 or a salt thereof.

7. A pharmaceutical composition containing a benzylamine derivative as recited in any one of claims 1 to 5 or a salt thereof, and a pharmaceutically acceptable carrier therefor.

8. Use, for producing a drug, of a benzylamine derivative as recited in any one of claims 1 to 5 or a salt thereof.

9. A method for treating irritable bowel syndrome, pain, anxiety, obstructive bronchial diseases, headache, or vomiting, characterized in that the method comprises administering, in an effective amount, a benzylamine derivative as recited in any one of claims 1 to 5 or a salt thereof.